Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients

The 1-year THALASSA study enrolled 166 patients with various non-transfusion-dependent thalassemia (NTDT) syndromes, degrees of iron burden and patient characteristics, and demonstrated the overall efficacy and safety of deferasirox in reducing liver iron concentration (LIC) in these patients. Here,...

Descripción completa

Detalles Bibliográficos
Autores principales: Taher, Ali T, Porter, John B, Viprakasit, Vip, Kattamis, Antonis, Chuncharunee, Suporn, Sutcharitchan, Pranee, Siritanaratkul, Noppadol, Galanello, Renzo, Karakas, Zeynep, Lawniczek, Tomasz, Habr, Dany, Ros, Jacqueline, Zhang, Yiyun, Cappellini, M Domenica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2013
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698696/
https://www.ncbi.nlm.nih.gov/pubmed/23553596
http://dx.doi.org/10.1002/ajh.23445

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698696/
https://www.ncbi.nlm.nih.gov/pubmed/23553596
http://dx.doi.org/10.1002/ajh.23445

Ejemplares similares